Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

References

• Barre-SinoussiFChermannJCReyFIsolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)Science198322045998688716189183
   PubMed Web of Science ®Google Scholar
• GalloRCSarinPSGelmannEPIsolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)Science198322045998658676601823
   PubMed Web of Science ®Google Scholar
• PerelsonASEssungerPCaoYDecay characteristics of HIV-1-infected compartments during combination therapyNature199738766291881919144290
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsWashington,DCDepartment of Health and Human Services Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdfAccessed January day 13, 2014
   Google Scholar
• RockstrohJKLennoxJLDeJesusELong-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1–infected patients: 156-week results from STARTMRKClin Infect Dis201153880781621921224
   PubMed Web of Science ®Google Scholar
• PandeyKKRaltegravir in HIV-1 infection: safety and efficacy in treatment-naive patientsClin Med Rev Ther201120124133022389581
   PubMedGoogle Scholar
• NguyenBYIsaacsRDTepplerHRaltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumAnn NY Acad Sci20111222838921434946
   PubMed Web of Science ®Google Scholar
• STRIBILD®[prescribing information]2013Foster City, CAGilead Sciences Inc.
   Google Scholar
• NachegaJBParientiJJUthmanOALower pill burden and once-daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trialsClin Infect Dis352014 Epub
   Web of Science ®Google Scholar
• EngelmanABushmanFDCraigieRIdentification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complexEMBO J1993128326932758344264
   PubMed Web of Science ®Google Scholar
• KrishnanLEngelmanARetroviral integrase proteins and HIV-1 DNA integrationJ Biol Chem201228749408584086623043109
   PubMed Web of Science ®Google Scholar
• JaskolskiMAlexandratosJNBujaczGWlodawerAPiecing together the structure of retroviral integrase, an important target in AIDS therapyFEBS J2009276112926294619490099
   PubMed Web of Science ®Google Scholar
• PandeyKKBeraSGrandgenettDPThe HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integrationBiochemistry201150459788979621992419
   PubMed Web of Science ®Google Scholar
• BeraSPandeyKKVoraACGrandgenettDPMolecular Interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integrationJ Mol Biol2009389118319819362096
   PubMed Web of Science ®Google Scholar
• HareSMaertensGNCherepanovP3′-processing and strand transfer catalysed by retroviral integrase in crystalloEMBO J201231133020302822580823
   PubMed Web of Science ®Google Scholar
• LiMMizuuchiMBurkeTRJrCraigieRRetroviral DNA integration: reaction pathway and critical intermediatesEMBO J20062561295130416482214
   PubMed Web of Science ®Google Scholar
• PandeyKKBeraSVoraACGrandgenettDPPhysical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitorsBiochemistry201049388376838720799722
   PubMed Web of Science ®Google Scholar
• PandeyKKBeraSZahmJInhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediateJ Virol20078122121891219917804497
   PubMed Web of Science ®Google Scholar
• PommierYJohnsonAAMarchandCIntegrase inhibitors to treat HIV/AIDSNat Rev Drug Discov20054323624815729361
   PubMed Web of Science ®Google Scholar
• HareSGuptaSSValkovEEngelmanACherepanovPRetroviral intasome assembly and inhibition of DNA strand transferNature2010464728623223620118915
   PubMed Web of Science ®Google Scholar
• HareSVosAMClaytonRFThuringJWCummingsMDCherepanovPMolecular mechanisms of retroviral integrase inhibition and the evolution of viral resistanceProc Natl Acad Sci USA201010746200572006221030679
   PubMed Web of Science ®Google Scholar
• SatoMMotomuraTAramakiHNovel HIV-1 integrase inhibitors derived from quinolone antibioticsJ Med Chem20064951506150816509568
   PubMed Web of Science ®Google Scholar
• RamanathanSMathiasAAGermanPKearneyBPClinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravirClin Pharmacokinet201150422924421348537
   PubMed Web of Science ®Google Scholar
• MinSSongIBorlandJPharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteersAntimicrob Agents Chemother201054125425819884365
   PubMed Web of Science ®Google Scholar
• KassahunKMcIntoshICuiDMetabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeDrug Metab Dispos20073591657166317591678
   PubMed Web of Science ®Google Scholar
• KawaguchiIIshikawaTIshibashiMIrieSKakeeASafety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers13th Conference on Retroviruses and Opportunistic InfectionsFebruary 5–8, 2006Denver, CO
   Google Scholar
• DeJesusEBergerDMarkowitzMAntiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsJ Acquir Immune Defic Syndr20064311516936557
   PubMed Web of Science ®Google Scholar
• MathiasAAWestSHuiJKearneyBPDose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposureClin Pharmacol Ther2009851647018815591
   PubMed Web of Science ®Google Scholar
• RamanathanSShenGHinkleJEnejosaJKearneyBPPharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavirJ Acquir Immune Defic Syndr200746216016617693892
   PubMed Web of Science ®Google Scholar
• RamanathanSShenGChengAKearneyBPPharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137J Acquir Immune Defic Syndr200745327427917414929
   PubMed Web of Science ®Google Scholar
• Collot-TeixeiraSDe LorenzoFWatersLImpact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expressionClin Pharmacol Ther200985437537819118379
   PubMed Web of Science ®Google Scholar
• FoisyMMYakiwchukEMHughesCAInduction effects of ritonavir: implications for drug interactionsAnn Pharmacother20084271048105918577765
   PubMed Web of Science ®Google Scholar
• MathiasAAGermanPMurrayBPPharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activityClin Pharmacol Ther201087332232920043009
   PubMed Web of Science ®Google Scholar
• GermanPWarrenDWeiLZhongLHuiJKearneyBPEffect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)912–152009San Francisco, CA.
   Google Scholar
• XuLLiuHMurrayBPDiscovery of GS-9350: A novel pharmacoenhancer without anti-HIV activity 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)912–152009San Francisco, CA.
   Google Scholar
• ShahBMSchaferJJPrianoJSquiresKECobicistat: a new boost for the treatment of human immunodeficiency virus infectionPharmacotherapy201333101107111623471741
   PubMed Web of Science ®Google Scholar
• GermanPWarrenDWestSHuiJKearneyBPPharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIVJ Acquir Immune Defic Syndr201055332332920683270
   PubMed Web of Science ®Google Scholar
• RamanathanSMathiasAWeiXPharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agentsJ Acquir Immune Defic Syndr2013641455023774876
   PubMed Web of Science ®Google Scholar
• KiserJJBumpassJBMeditzALEffect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteersAntimicrob Agents Chemother201054124999500320921313
   PubMed Web of Science ®Google Scholar
• CottrellMLHadzicTKashubaADClinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravirClin Pharmacokinet2013521198199423824675
   PubMed Web of Science ®Google Scholar
• KlibanovOMElvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infectionCurr Opin Investig Drugs2009102190200
   PubMedGoogle Scholar
• CohenCElionRRuanePRandomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionAIDS2011256F7F1221412057
   PubMed Web of Science ®Google Scholar
• SaxPEDeJesusEMillsACo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLancet201237998352439244822748591
   PubMed Web of Science ®Google Scholar
• ZolopaASaxPEDeJesusEA randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr20136319610023392460
   PubMed Web of Science ®Google Scholar
• ElionRCohenCWardDEvaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyHIV Clin Trials20089421322418753116
   PubMed Web of Science ®Google Scholar
• GermanPLiuHCSzwarcbergJEffect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal functionJ Acquir Immune Defic Syndr2012611324022732469
   PubMed Web of Science ®Google Scholar
• HallAMHendryBMNitschDConnollyJOTenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidenceAm J Kidney Dis201157577378021435764
   PubMed Web of Science ®Google Scholar
• MalikAAbrahamPMalikNAcute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment – case report and review of literatureJ Infect2005512E61E6516038754
   PubMedGoogle Scholar
• WohlDACohenCGallantJEA randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsJ Acquir Immune Defic Syndr2014653e118e12024256630
   PubMed Web of Science ®Google Scholar
• LennoxJLDejesusEBergerDSRaltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJ Acquir Immune Defic Syndr2010551394820404738
   PubMed Web of Science ®Google Scholar
• MurrayJMEmerySKelleherADAntiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseAIDS200721172315232118090280
   PubMed Web of Science ®Google Scholar
• RockstrohJKDeJesusEHenryKA randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr201362548348623337366
   PubMed Web of Science ®Google Scholar
• ClumeckNMolinaJMHenryKA randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsJ Acquir Immune Defic Syndr2014653e121e12424346640
   PubMed Web of Science ®Google Scholar
• DeJesusERockstrohJKHenryKCo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialLancet201237998352429243822748590
   PubMed Web of Science ®Google Scholar
• AryaVFlorianJMarcusKAReynoldsKSLewisLLSherwatAIDoes an increase in serum creatinine always reflect renal injury? The case of STRIBILD®J Clin Pharmacol2013543279281
   Web of Science ®Google Scholar
• MolinaJMLamarcaAAndrade-VillanuevaJEfficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyLancet Infect Dis2012121273522015077
   PubMed Web of Science ®Google Scholar
• ElionRMolinaJMRamon Arribas LopezJA randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsJ Acquir Immune Defic Syndr201363449449723807156
   PubMed Web of Science ®Google Scholar
• CrofootGOrtizRMillsASafety and tolerability of switching from twice daily raltegravir plus truvada to STRIBILD in virologically suppressed, HIV-1-infected subjects at week 247th IAs Conference on HIV Pathogenesis, Treatment and PreventionJun 30–July 3, 2013Kuala Lumpur, Malaysia
   Google Scholar
• ShimuraKKodamaESakagamiYBroad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)J Virol200882276477417977962
   PubMed Web of Science ®Google Scholar
• GoethalsOClaytonRVan GinderenMResistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitorsJ Virol20088221103661037418715920
   PubMed Web of Science ®Google Scholar
• MargotNAHluhanichRMJonesGSIn vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4Antiviral Res201293228829622197635
   PubMed Web of Science ®Google Scholar
• MespledeTQuashiePKOsmanNViral fitness cost prevents HIV-1 from evading dolutegravir drug pressureRetrovirology2013102223432922
   PubMed Web of Science ®Google Scholar
• QuashiePKMespledeTHanYSCharacterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravirJ Virol20128652696270522205735
   PubMed Web of Science ®Google Scholar
• BlancoJLVargheseVRheeSYGatellJMShaferRWHIV-1 integrase inhibitor resistance and its clinical implicationsJ Infect Dis201120391204121421459813
   PubMed Web of Science ®Google Scholar
• ZahmJABeraSPandeyKKMechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistanceAntimicrob Agents Chemother20085293358336818591263
   PubMed Web of Science ®Google Scholar
• MarinelloJMarchandCMottBTBainAThomasCJPommierYComparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutantsBiochemistry200847369345935418702518
   PubMed Web of Science ®Google Scholar
• MetifiotMMaddaliKNaumovaAZhangXMarchandCPommierYBiochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirBiochemistry201049173715372220334344
   PubMed Web of Science ®Google Scholar
• AbramMEHluhanichRMGoodmanDDImpact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessAntimicrob Agents Chemother20135762654266323529738
   PubMed Web of Science ®Google Scholar
• ChristFVoetAMarchandARational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replicationNat Chem Biol20106644244820473303
   PubMed Web of Science ®Google Scholar
• EngelmanAKesslJJKvaratskheliaMAllosteric inhibition of HIV-1 integrase activityCurr Opin Chem Biol201317333934523647983
   PubMed Web of Science ®Google Scholar